A phase I, single center, randomized, double-blind, placebo controlled, single dose (SD) and multiple dose (MD), dose-escalation clinical trial to evaluate the tolerability and preliminary antiviral activity of therapeutic hepatitis B adenovirus injection (T101) in chronic hepatitis B patients.
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2018
At a glance
- Drugs T 101 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Transgene Tasly (Tianjin) BioPharmaceutical
- 21 Mar 2018 According to a Transgene media release, full results are expected in 2H 2018.
- 17 Jan 2018 According to a Transgene media release, data from the trial is expected at the beginning of 2019.
- 17 Jan 2018 Status changed from not yet recruiting to recruiting, according to a Transgene media release.